Carregant...
The clinical development of obinutuzumab for the treatment of follicular lymphoma
Impressive progress has been made in recent decades for advanced-stage follicular lymphoma with the availability of anti-CD20 monoclonal antibodies, initially rituximab and more recently obinutuzumab. Obinutuzumab is a unique, third-generation, fully humanized glycoengineered IgG(1) type II anti-CD2...
Guardat en:
| Publicat a: | Cancer Manag Res |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5391868/ https://ncbi.nlm.nih.gov/pubmed/28435325 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S114526 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|